leflunomide has been researched along with Inflammation in 20 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 7.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "The association between serum uric acid concentrations and inflammation in patients with rheumatoid arthritis (RA) has been still controversial." | 7.81 | Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. ( Choe, JY; Kim, SK, 2015) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 7.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "To examine the effect of leflunomide (LEF) on T cell activation-induced inflammatory cytokine production in human peripheral blood mononuclear cells (PBMC) and rat established adjuvant-induced arthritis (AIA), and compare these effects with methotrexate (MTX) and FK506 (tacrolimus), focusing on improvement of joint function in AIA." | 7.72 | Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. ( Magari, K; Miyata, S; Mutoh, S; Nishigaki, F; Ohkubo, Y, 2004) |
| "Leflunomide is an effective disease modifying antirheumatic drug (DMARD) in RA." | 5.33 | Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. ( Beneytout, JL; Bertin, P; Léger, DY; Liagre, B; Trèves, R; Vergne-Salle, P, 2005) |
| " Leflunomide (CAS 75706-12-6), a drug approved for the treatment of treat rheumatoid arthritis (RA), was identified as an inhibitor of DHODH." | 4.87 | Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. ( Leban, J; Vitt, D, 2011) |
| "Leflunomide is a low-molecular-weight compound that is widely used in the treatment of rheumatoid arthritis." | 3.85 | The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. ( Cho, ML; Jhun, JY; Kim, EK; Lee, HJ; Lee, WS; Min, JK; Moon, SJ; Park, SH, 2017) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 3.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "Omeprazole does not inhibit Th2 cytokine-stimulated eotaxin-3 expression by esophageal fibroblasts, suggesting that PPIs will have limited impact on subepithelial EoE processes such as fibrosis." | 3.83 | JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. ( Cheng, E; Huo, X; Park, JY; Souza, RF; Spechler, SJ; Wang, DH; Wilson, KS; Yu, C; Zhang, Q; Zhang, X, 2016) |
| "The association between serum uric acid concentrations and inflammation in patients with rheumatoid arthritis (RA) has been still controversial." | 3.81 | Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. ( Choe, JY; Kim, SK, 2015) |
| "Iguratimod, a novel disease-modifying antirheumatic drug, which is now used in clinics in China and Japan, has been confirmed as a highly efficacious and safe drug for rheumatoid arthritis therapy." | 3.79 | A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. ( Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q, 2013) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 3.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "A series of leflunomide (1a) analogues were examined for antiinflammatory activity using the carrageenan-induced paw edema assay." | 3.72 | Leflunomide analogues as potential antiinflammatory agents. ( Chiu, HF; Huang, WH; Lee, AR; Yang, CL, 2003) |
| "To examine the effect of leflunomide (LEF) on T cell activation-induced inflammatory cytokine production in human peripheral blood mononuclear cells (PBMC) and rat established adjuvant-induced arthritis (AIA), and compare these effects with methotrexate (MTX) and FK506 (tacrolimus), focusing on improvement of joint function in AIA." | 3.72 | Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. ( Magari, K; Miyata, S; Mutoh, S; Nishigaki, F; Ohkubo, Y, 2004) |
| "Treatment with leflunomide can improve these parameters except systolic blood pressure, BG and HbAlc." | 1.38 | Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats. ( Liu, JP; Ren, XJ; Wang, H; Wang, JY; Yu, WM, 2012) |
| "Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses." | 1.38 | Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells. ( Baban, B; Liu, JY; Mozaffari, MS, 2012) |
| "Leflunomide is an effective disease modifying antirheumatic drug (DMARD) in RA." | 1.33 | Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. ( Beneytout, JL; Bertin, P; Léger, DY; Liagre, B; Trèves, R; Vergne-Salle, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Barbarroja, N | 1 |
| Ruiz-Ponce, M | 1 |
| Cuesta-López, L | 1 |
| Pérez-Sánchez, C | 1 |
| López-Pedrera, C | 1 |
| Arias-de la Rosa, I | 1 |
| Collantes-Estévez, E | 1 |
| Didier, PJ | 1 |
| Adrián, ML | 1 |
| Paola, SA | 1 |
| Mauricio, FS | 1 |
| Omar, CS | 1 |
| Liset, RY | 1 |
| Luis, RJ | 1 |
| Luo, Q | 1 |
| Sun, Y | 1 |
| Liu, W | 1 |
| Qian, C | 1 |
| Jin, B | 1 |
| Tao, F | 1 |
| Gu, Y | 1 |
| Wu, X | 1 |
| Shen, Y | 1 |
| Xu, Q | 1 |
| Jiang, A | 1 |
| Wang, J | 1 |
| Joshi, M | 1 |
| Christoforidis, JB | 1 |
| Choe, JY | 1 |
| Kim, SK | 1 |
| Ficjan, A | 1 |
| Husic, R | 1 |
| Gretler, J | 1 |
| Lackner, A | 1 |
| Graninger, WB | 1 |
| Gutierrez, M | 1 |
| Duftner, C | 1 |
| Hermann, J | 1 |
| Dejaco, C | 1 |
| Deng, F | 1 |
| Zhang, P | 1 |
| Feng, J | 1 |
| Wang, L | 1 |
| Cheng, E | 1 |
| Zhang, X | 1 |
| Wilson, KS | 1 |
| Wang, DH | 1 |
| Park, JY | 1 |
| Huo, X | 1 |
| Yu, C | 1 |
| Zhang, Q | 1 |
| Spechler, SJ | 1 |
| Souza, RF | 1 |
| Moon, SJ | 1 |
| Kim, EK | 1 |
| Jhun, JY | 1 |
| Lee, HJ | 1 |
| Lee, WS | 1 |
| Park, SH | 1 |
| Cho, ML | 1 |
| Min, JK | 1 |
| Cutolo, M | 1 |
| Villaggio, B | 1 |
| Pizzorni, C | 1 |
| Paolino, S | 1 |
| Moretti, S | 1 |
| Gallo, F | 1 |
| Bonassi, S | 1 |
| Sulli, A | 1 |
| Seriolo, B | 1 |
| Montagna, P | 1 |
| Soldano, S | 1 |
| Leban, J | 1 |
| Vitt, D | 1 |
| Yu, WM | 1 |
| Wang, H | 1 |
| Ren, XJ | 1 |
| Liu, JP | 1 |
| Wang, JY | 1 |
| Baban, B | 1 |
| Liu, JY | 1 |
| Mozaffari, MS | 1 |
| Huang, WH | 1 |
| Yang, CL | 1 |
| Lee, AR | 1 |
| Chiu, HF | 1 |
| Magari, K | 1 |
| Miyata, S | 1 |
| Nishigaki, F | 1 |
| Ohkubo, Y | 1 |
| Mutoh, S | 1 |
| Vergne-Salle, P | 1 |
| Léger, DY | 1 |
| Bertin, P | 1 |
| Trèves, R | 1 |
| Beneytout, JL | 1 |
| Liagre, B | 1 |
| Bartlett, RR | 1 |
| Anagnostopulos, H | 1 |
| Zielinski, T | 1 |
| Mattar, T | 1 |
| Schleyerbach, R | 1 |
| Gregory, CR | 1 |
| Stewart, A | 1 |
| Sturges, B | 1 |
| DeManvelle, T | 1 |
| Cannon, A | 1 |
| Ortega, T | 1 |
| Harb, M | 1 |
| Morris, RE | 1 |
| Hirschelmann, R | 1 |
| Schade, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Exploratory, Randomized, Double-blind, Parallel-group, Multicenter Study to Compare Secukinumab 300 mg With Placebo After 16 Weeks of Treatment in Adults With Moderate to Severe Plaque Psoriasis and Subclinical Enthesitis Measured by Musculoskeletal Ul[NCT04488185] | Phase 4 | 0 participants (Actual) | Interventional | 2020-11-02 | Withdrawn (stopped due to low recruitment) | ||
| Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS[NCT03464448] | 30 participants (Actual) | Observational | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for leflunomide and Inflammation
| Article | Year |
|---|---|
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Dis | 2022 |
Systemic treatments for noninfectious vitreous inflammation.
Topics: Adalimumab; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Eye Diseases; Humans; Immuno | 2013 |
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Dihydroorotate | 2011 |
Effects of leflunomide on immune responses and models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Autoimmune Diseases; Cytokines | 1993 |
16 other studies available for leflunomide and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
CLIPPERS syndrome responsive to Leflunomide: A case report.
Topics: Adult; Brain Diseases; Cerebellum; Follow-Up Studies; Humans; Immunosuppressive Agents; Inflammation | 2018 |
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthri | 2013 |
Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide.
Topics: Aged; Arthritis, Rheumatoid; Female; Glomerular Filtration Rate; Humans; Inflammation; Isoxazoles; L | 2015 |
Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score).
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Bone and Bones; Feasibility Studies; Female; Foll | 2014 |
[Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis].
Topics: Animals; Chronic Disease; Disease Models, Animal; Glomerulonephritis; Inflammation; Interleukin-6; I | 2016 |
JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE.
Topics: Cell Line, Transformed; Chemokine CCL26; Chemokines, CC; Eosinophilic Esophagitis; Eosinophils; Epit | 2016 |
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid | 2017 |
Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Cells, Cultured; Dose-Resp | 2010 |
Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Chemokine CCL2; Creatinine; Cytoprotection; Diabetes | 2012 |
Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Gene Expression Regulation; Inflammatio | 2012 |
Leflunomide analogues as potential antiinflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Edema; Inflammat | 2003 |
Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bone Marrow Cells; CD28 Antigens; CD3 C | 2004 |
Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Topics: Active Transport, Cell Nucleus; Aniline Compounds; Anti-Inflammatory Agents; Apoptosis; Arthritis, R | 2005 |
Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
Topics: Aniline Compounds; Animals; Crotonates; Dog Diseases; Dogs; Female; Hydroxybutyrates; Immune System | 1998 |
6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
Topics: Acute-Phase Reaction; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experi | 1988 |